High-dose chemotherapy with autologous stem cell support in advanced ovarian cancer

Annals of Medicine

Volumn 28, Issue 2, 1996, Pages 151-158

  Grénman, Seija E ^a   Rantanen, Virpi T ^a   Salmi, Tuula A ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Autologous stem cell transplantation; High dose chemotherapy; Ovarian carcinoma; Peripheral blood stem cell transplantation

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; MITOXANTRONE; PACLITAXEL; TAXANE DERIVATIVE; THIOTEPA; VINCA ALKALOID;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; HUMAN; LAPAROTOMY; OVARY CARCINOMA; PRIORITY JOURNAL; REMISSION; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0029875816     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899609092940     Document Type: Review

References (64)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the world-wide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594-606.
2. Piver MS, Baker TR, Piedmonte M, Sandecki AM. Epidemiology and etiology of ovarian cancer. Semin Oncol 1991; 18: 177-85.
3. Pettersson F (Ed.) Annual Report on the Results of the Treatment in Gynecological Cancer. FIGO, 1994.
4. Colombo N, Pittelli M, Parma G, et al. Cisplatin dose intensity in advanced ovarian cancer: a randomized study of conventional dose vs. dose-intense cisplatin monotherapy. Proc Am Soc Clin Oncol 1993; 12: 255.
5. Podczaski E, Manetta A, Kaminski P, et al. Survival of patients with ovarian epithelial carcinomas after second-look laparotomy. Gynecol Oncol 1990; 36: 43-7.
6. Coldman A, Goldie J. Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin Oncol 1987; 14: 29-33.
7. Kaye SB, Lewis CR, Paul J, et al. Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992; 340: 329-33.
8. McGuire WP, Hoskins WJ, Brady MF, et al. Assesment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995a; 13: 1589-99.
9. Ozols RF, Thigpen JT, Dauplat J, et al. Dose intensity. Ann Oncol 1993; 4 (Suppl): S49-56.
10. Thigpen T, Vance R, Puneky L, Khansur T. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol 1994a; 55: 897-107.
11. de Vries EGE, Hamilton TC, Lind M, Dauplat J, Neijt J, Ozols RF. Drug resistance, supportive care and dose intensity. Ann Oncol 1993; 4 (Suppl): S57-62.
12. Menichella G, Pierelli L, Foddai M, et al. Autologous blood stem cell harvesting and transplantation in patients with advanced ovarian cancer. Br J Haematol 1991; 79: 444-50.
13. Murakami M, Shinozuka T, Kuroshima Y, Tokuda Y, Tajima T. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of malignant ovarian tumours. Semin Oncol 1994; 21 (Suppl): 29-32.
14. Benedetti-Panici P, Greggi S, Scambia G, et al. High-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Ann Med 1995; 27: 133-8.
15. Fenelly D, Schneider D, Spriggs, et al. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol 1995; 13: 1160-6.
16. Woodhouse JR, Ferry DR. The genetic basis of resistance to cancer chemotherapy. Ann Med 1995; 27: 157-67.
17. Lai G-M, Ozols RF, Smyth JF, Young RC, Hamilton TC. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol 1988; 37: 4597-600.
18. Parker RJ, Eastman A, Bostick-Bruton F, Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991; 87: 772-7.
19. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
20. Kristensen G, Baekelandt M, Holm R, et al. PGP expression as a possible marker for response to cisplatin-epirubicin as a first-line treatment in advanced ovarian cancer. Gynecol Oncol 1995; 56: 110.
21. Holzmayer T, Hilsenbeck S, Von Hoff DD, et al. Clinical correlates of MDRI (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 1992; 84: 19: 1486-91.
22. O'Dwyer PJ, Hamilton TC, Young RC, et al. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximin: clinical and biochemical results. J Natl Cancer Inst 1992; 84: 264-7.
23. O'Dwyer PJ, LaCreta F, Nash J, et al. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res 1991; 51: 6059-65.
24. Sessa C, Zucchetti M, Davoli E, et al. Phase I and clinical pharmacologic evaluation of aphidicolin glycinate. J Natl Cancer Inst 1991; 83: 1160-9.
25. Lowe SW, Ruley HE, Jacks T, et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
26. Hockenbery YD, Nunez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-6.
27. Alberts DS, Young L, Mason NL, et al. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 1985; 12 (Suppl): 38-42.
28. Skipper HE. Dose intensity vs. total dose of chemotherapy: an experimental basis. In: De Vita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. New York: JB Lippincott, 1990: 43-64.
29. Levin L, Hryniuk WM. Dose-intensity analysis of chemotherapeutic agents in ovarian cancer. J Clin Oncol 1987; 5: 756-67.
30. Levin L, Simon R, Hryniuk W. Importance of multiagent chemotherapy regimens in ovarian cancer: dose intensity analysis. J Natl Cancer Inst 1993; 85: 1732-42.
31. Ben-David Y, Rosen B, Franssen E, et al. Meta-analysis comparing cisplatin total dose intensity and survival. Gynecol Oncol 1995; 59: 93-101.
32. Caldas C, Morris LE, McGuire WP. Salvage therapy in epithelial ovarian cancer. Obstet Gynecol Clin North Am 1994; 21: 179-94.
33. Behrens BC, Hamilton TC, Masuda H, et al. Characteristics of cis-diamminedochloroplatinum (II)resistant human ovarian cell line and its evaluation of platinum analogues. Cancer Res 1987; 47: 414-8.
34. Bertelssen K. Optimal chemotherapy of ovarian cancer with an old regimen. Ann Med 1995; 27: 121-5.
35. McGuire WP, Hoskins WJ, Brady MF, et al. Taxol and cisplatin (TP) improves outcome in advanced ovarian cancer (AOC) as compare to cytoxan and cisplatin (CP). Proc Am Soc Clin Oncol 1995b: 14: 275.
36. Trimble EL, Arbuck SG, McGuire WP. Options for primary chemotherapy of epithelial ovarian cancer: Taxanes. Gynecol Oncol 1994; 55: S114-21.
37. Christian MC, Trimble EL. Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol 1994; 55: S143-50.
38. Dauplat J, Legros M, Condat P, Ferrieri JP, Ben Ahmed S, Plagne R. High-dose melphalan and autologous bone marrow support for treatment of ovarian carcinoma with positive second-look operation. Gynecol Oncol 1989; 34: 294-8.
39. Viens P, Maraninchi D, Legros F, et al. High-dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France. Bone Marrow Transplant 1990; 5: 227-33.
40. Legros M, Fluery J, Cure H, et al. High dose chemotherapy (HDC) and autologous bone marrow transplant (ABMT) in 31 advanced ovarian cancers: long term results. Proc Am Soc Clin Oncol 1992; 11: 222.
41. Mulder POM, Willemse PHB, Aalders JG, et al. High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer. Eur J Cancer Clin Oncol 1989; 25: 645-9.
42. Shea TC, Flaherty M, Elias A, et al. A phase I clinical and pharmacokinetic study and carboplatin and autologous bone marrow support. J Clin Oncol 1989; 7: 651-61.
43. Shpall EJ, Clarke-Pearson D, Soper JT, et al. High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol 1990; 38: 386-91.
44. Lotz JP, Machover D, Malassagne B, et al. Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, Ifosfamide, and Carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumours. J Clin Oncol 1991; 9: 1860-70.
45. Rebollo JH, Martin AS, Fernandez HO, et al. High dose combination of carboplatin (CBDCA) and etoposide (VP-16) followed by peripheral blood stem cell (PBSC) transplantation in the treatment of ovarian carcinoma. Proc Am Assos Cancer Res 1991; 32: 172.
46. Collins RH, Pineiro L, Fay JW. High-dose chemotherapy and autologous bone marrow transplantation for advanced ovarian cancer. Proc Am Soc Clin Oncol 1992; 11: 233.
47. Extra JM, Dieras W, Giacchetti S, et al. High-dose chemotherapy (HCT) with autologous bone marrow reinfusion (ABMR) as consolidation therapy for patients (PTS) with advanced ovarian adeno carcinoma (AO). Proc Am Soc Clin Oncol 1992; 11: 234.
48. Shea TC, Storniolo AM, Mason JR, et al. High-dose intravenous (IV) and intraperitoneal (IP) combination chemotherapy with autologous stem cell rescue for patients with advanced ovarian cancer. Proc Am Soc Clin Oncol 1992; 11: 236.
49. Lotz JP, Machover D, Bellaiche A, et al. Tandem high-dose (HD) chemotherapy (CT) with VM-26, ifosfamide (IFM), and carboplatin (CBDCA) with autologous bone marrow transplantation (ABMT) for patients with stage III C - IV ovarian cancer (OC). Proc Am Soc Clin Oncol 1993; 12: 257.
50. Broun ER, Belinson JL, Berek JS, et al. Salvage therapy for recurrent and refractory ovarian cancer with high-dose chemotherapy and autologous bone marrow support: a Gynecologic Oncology Group pilot study. Gynecol Oncol 1994; 54: 142-6.
51. Stiff P, Bayer R, Camarda M, et al. A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome. Gynecol Oncol 1995; 57: 278-85.
52. Shpall EJ, Cagnoni PJ, Bearman SI, et al. High-dose chemotherapy with autologous hematopoetic cell support (AHCS) for the treatment of epithelial ovarian cancer. Am Soc Clin Oncol Educational Book 1995a; 360-4.
53. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994b; 12: 1748-53.
54. Williams CJ, Stewart L, Parmar M, et al. Meta-analysis of the role of platinum compounds in advanced ovarian cancer. Semin Oncol 1992; 19: 120-8.
55. Neijt JP, Bokkel Huinink WW, et al. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991; 27: 1367-72.
56. Muramatsu T, Shinozuka T, Hirasawa T, et al. High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) in epithelial ovarian cancer. Int J Gynecol Cancer 1995; 5 (Suppl 1): 44.
57. Shpall EJ, Jones RB, Bearman SI, Purdy MP. Future strategies for the treatment of advanced epithelial ovarian cancer using high-dose chemotherapy and autologous bone marrow support. Gynecol Oncol 1994; 54: 357-61.
58. Pujade-Lauraine E, Extra JM. Place of intensive therapy in ovarian cancer. Eurocancer 95, Paris 1995; 217-8.
59. Alberts D, Liu P, Hannigan E, et al. Phase III study of intraperitoneal (IP) cisplatin (CDDP)/intravenous (IV) cyclophosphamide (CPA) vs. IV CDDP/IV CPA in patients with optimal disease stage III ovarian cancer: a SWOG-GOG-ECOG intergroup study (INT 0051). Proc Am Soc Clin Oncol 1995; 13: 273.
60. Kohn EC, Sarosy G, Bicher A, et al. Dose-intense taxol: high response rate in patients with platinum resistant ovarian cancer. J Natl Cancer Inst 1994; 86: 18-24.
61. Cagnoni PJ, Stemmer SM, Matthes S, et al. Phase I trial of high dose paclitaxel (Taxol), cyclophosphamide and cicplatin with autolougs hematopoetic progenitor cell rescue. Proc Am Soc Clin Oncol 1995; 14: 477.
62. Swenerton K, Eisenhauer E, ten Bokkel Huinink W, et al. Taxol in relapsed ovarian cancer: high vs. low dose and short vs. long infusion. A European Canadian study coordinated by the NCI Canada Clinical Trials Group. Proc Am Soc Clin Oncol 1993; 12: 256.
63. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994; 55: S4-14.
64. Forsström J, Dalton KJ. Artificial neural networks for decision support in clinical medicine. Ann Med 1995; 27: 509-17.